spot_img
Tuesday, June 28, 2022
More
    HomeHealthFDA scolds Lilly for misleading Instagram post about diabetes drug

    FDA scolds Lilly for misleading Instagram post about diabetes drug

    -



    Eli Lilly (LLY) was rebuked by the U.S. Meals and Drug Administration for operating a deceptive Instagram submit that omitted threat details about its best-selling Trulicity diabetes drugs, marking the second time in as many months the regulator scolded the corporate for failing to observe promoting guidelines.

    Within the newest transgression, the FDA famous the Instagram post made an incorrect declare that the drug might decrease blood sugar ranges and displayed key details about dangers and acceptable use in small, fast-moving kind on the display screen. But the advantages of the diabetes drug have been prominently featured in “colourful, compelling, and attention-grabbing fast-paced visuals.”

    Unlock this text by subscribing to STAT+ and luxuriate in your first 30 days free!

    GET STARTED





    Source link

    Related articles

    Stay Connected

    0FansLike
    0FollowersFollow
    3,372FollowersFollow
    0SubscribersSubscribe
    spot_img

    Latest posts